A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Julio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II randomized controlled trial evaluated the efficacy of subcutaneous mosunetuzumab combined with polatuzumab vedotin (Mosun-Pola) versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed or refractory large B-cell lymphoma. The study found a best objective response rate of 77.5% for Mosun-Pola compared to 50.0% for R-Pola, indicating a significant improvement in treatment outcomes.
Key findings
- Best objective response rate was 77.5% for Mosun-Pola versus 50.0% for R-Pola.
- Complete response rates were 55.0% for Mosun-Pola and 35.0% for R-Pola.
- Median progression-free survival was 25.4 months for Mosun-Pola compared to 6.4 months for R-Pola.
- Cytokine release syndrome occurred in 12.5% of Mosun-Pola-treated patients.
Why it matters
The findings suggest that subcutaneous mosunetuzumab in combination with polatuzumab vedotin may offer superior efficacy compared to the standard treatment in patients with relapsed or refractory large B-cell lymphoma, potentially influencing treatment decisions in this patient population.